What is the recommended IV chelation regimen for managing chronic iron overload (iron toxicity)?

IV Iron Chelation for Chronic Iron Overload

For chronic iron overload requiring IV chelation, deferoxamine (DFO) is the treatment of choice, administered as a subcutaneous or intravenous infusion over 8-24 hours, typically 5-7 days per week, with dosing tailored to iron burden severity. 1, 2

Primary Chelation Regimen

Deferoxamine (DFO) remains the gold standard IV/subcutaneous chelator, particularly for:

• Severe iron overload requiring urgent intervention
• Emergency conditions with life-threatening cardiac iron overload
• Patients who cannot tolerate or have failed oral chelators 1, 2

Dosing Strategy

• Standard dosing: Subcutaneous or IV infusion over 8-24 hours
• Frequency: Minimum 5 times per week, up to daily administration 3, 4
• Dose adjustment: Required in renal failure; contraindicated in pregnancy 1

Alternative Oral Chelators (Off-Label for Some Conditions)

While the question asks about IV chelation, understanding the full chelation landscape is critical:

Deferasirox (DFX) - Oral Option

• Starting dose: 10 mg/kg daily (dispersible tablets)
• Reduced median serum ferritin by 75% over 48 weeks in haemochromatosis patients 1
• Monitoring: Monthly liver and renal function; annual audiological and ophthalmological review 1
• Often used as first-line in transfusion-dependent conditions 2

Deferiprone (DFP) - Oral Option with Caution

• Critical warning: Significant haematological toxicity risk, including fatal agranulocytosis in haemochromatosis patients with cardiac iron overload 1
• May be useful despite neutropenia risk in specific cases 2
• Requires careful patient selection and monitoring

Combination Therapy for Severe Cases

In life-threatening cardiac iron overload (particularly juvenile haemochromatosis), combination therapy with oral DFP plus IV DFO has been described 1. This aggressive approach is reserved for:

• Severe clinical manifestations
• Cardiac dysfunction from iron overload
• Cases requiring rapid iron mobilization

Monitoring Parameters

Target serum ferritin during treatment:

• Induction phase: Reduce to <250 ng/mL or 50 μg/L 1
• Monitoring frequency: Every 3-6 months 4
• Additional assessments: Liver and cardiac iron concentration via MRI when available 5

Critical Pitfalls to Avoid

1. DFO compliance issues: The 8-24 hour infusion requirement leads to poor adherence—patient education and support are essential 3
2. Deferoxamine toxicity: Monitor for ototoxicity, cataracts, growth impairment in children, and increased infection susceptibility 4
3. Deferiprone in haemochromatosis with cardiac involvement: Avoid due to agranulocytosis risk 1
4. Cost considerations: DFO treatment costs approximately £19,000 annually per patient, with equipment and home healthcare comprising 67% of costs 3

Special Populations

Patients intolerant to phlebotomy (advanced disease, low baseline hemoglobin, cardiac impairment): Consider personalized mini-phlebotomies plus subcutaneous DFO infusion—refer to specialized centers 1

Transfusion-dependent patients: Initiate chelation when hepatic iron content exceeds 120 μmol/g 2

The evidence strongly supports DFO as the IV chelation standard, though the burden of administration necessitates careful patient selection and support systems to ensure compliance and therapeutic success.